Relationship between serum heparanase and microscopic venous invasion in patients with hepatocellular carcinoma

American Journal of Clinical Pathology

Volumn 134, Issue 2, 2010, Pages 242-248

  Wang, Gui Bo ^a   Zhou, Xin Yu ^a   Wang, Xiao Qin ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Heparanase; Hepatocellular carcinoma; Microscopic venous invasion; Prognosis

Indexed keywords

HEPARANASE; VASCULOTROPIN;

ADULT; ADVANCED CANCER; ARTICLE; BLOOD LEVEL; CANCER INVASION; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LIVER CELL CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MICROSCOPY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT OUTCOME; TUMOR VOLUME;

CARCINOMA, HEPATOCELLULAR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLUCURONIDASE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77955623464     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCPPJM6VHG4LPJX     Document Type: Article

References (28)

1. Lau WY, Lai EC. Hepatocellular carcinoma: current management and recent advances. Hepatobiliary Pancreat Dis Int. 2008;7:237-257.
2. Lu X, Zhao H, Yang H, et al. A prospective clinical study on early recurrence of hepatocellular carcinoma after hepatectomy. J Surg Oncol. 2009;100:488-493.
3. Woo SM, Ryu JK, Lee SH, et al. Recurrence and prognostic factors of ampullary carcinoma after radical resection: comparison with distal extrahepatic cholangiocarcinoma. Ann Surg Oncol. 2007;14:3195-3201.
4. Ishimura T, Sakai I, Hara I, et al. Microscopic venous invasion in renal cell carcinoma as a predictor of recurrence after radical surgery. Int J Urol. 2004;11:264-268. (Pubitemid 38758140)
5. Vlodavsky I, Miao HQ, Medalion B, et al. Involvement of heparan sulfate and related molecules in sequestration and growth promoting activity of fibroblast growth factor. Cancer Metastasis Rev. 1996;15:177-186.
6. Fux L, Ilan N, Sanderson RD, et al. Heparanase: busy at the cell surface. Trends Biochem Sci. 2009;34:511-519.
7. Nobuhisa T, Naomoto Y, Takaoka M, et al. Emergence of nuclear heparanase induces differentiation of human mammary cancer cells. Biochem Biophys Res Commun. 2005;331:175-180.
8. Xie ZJ, Liu Y, Jia LM, et al. Heparanase expression, degradation of basement membrane and low degree of infiltration by immunocytes correlate with invasion and progression of human gastric cancer. World J Gastroenterol. 2008;14:3812-3818.
9. Shafat I, Barak AB, Postovsky S, et al. Heparanase levels are elevated in the plasma of pediatric cancer patients and correlate with response to anticancer treatment. Neoplasia. 2007;9:909-916.
10. Nobuhisa T, Naomoto Y, Ohkawa T, et al. Heparanase expression correlates with malignant potential in human colon cancer. J Cancer Res Clin Oncol. 2005;131:229-237.
11. Okawa T, Naomoto Y, Nobuhisa T, et al. Heparanase is involved in angiogenesis in esophageal cancer through induction of cyclooxygenase-2. Clin Cancer Res. 2005;11:7995-8005.
12. Liu CJ, Lee PH, Lin DY, et al. Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: a randomized phase II trial for safety and optimal dosage. J Hepatol. 2009;50:958-968.
13. Rohloff J, Zinke J, Schoppmeyer K, et al. Heparanase expression is a prognostic indicator for postoperative survival in pancreatic adenocarcinoma. Br J Cancer. 2002;86:1270-1275.
14. Shinyo Y, Kodama J, Hongo A, et al. Heparanase expression is an independent prognostic factor in patients with invasive cervical cancer. Ann Oncol. 2003;14:1505-1510.
15. Lerner I, Baraz L, Pikarsky E, et al. Function of heparanase in prostate tumorigenesis: potential for therapy. Clin Cancer Res. 2008;14:668-676.
16. Khasraw M, Pavlakis N, McCowatt S, et al. Multicentre phase I/II study of PI-88, a heparanase inhibitor in combination with docetaxel in patients with metastatic castrate-resistant prostate cancer [published online ahead of print November 16, 2009]. Ann Oncol. 2010;21:1302-1307. doi:10.1093/annonc/mdp524.
17. Lewis KD, Robinson WA, Millward MJ, et al. A phase II study of the heparanase inhibitor PI-88 in patients with advanced melanoma. Invest New Drugs. 2008;26:89-94.
18. Jayson G, Gallagher J. Heparin oligosaccharides: inhibitors of the biological activity of bFGF on Caco2 cells. Br J Cancer. 1997;75:9-16.
19. Ornstein DL, Zacharski LR. Activity of heparins in experimental models of malignancy: possible explanations for anticancer effects in humans. Clin Hemorheol Microcirc. 2002;26:33-40.
20. Sobin LH, Fleming ID. TNM Classification of Malignant Tumors, fifth edition (1997). Cancer. 1997;80:1803-1804.
21. Edmondson HA, Steiner PE. Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer. 1954;7:462-503.
22. Sugimachi K, Maehara S, Tanaka S, et al. Repeat hepatectomy is the most useful treatment for recurrent hepatocellular carcinoma. J Hepatobiliary Pancreat Surg. 2001;8:410-416.
23. Sumie S, Kuromatsu R, Okuda K, et al. Microvascular invasion in patients with hepatocellular carcinoma and its predictable clinicopathological factors. Ann Surg Oncol. 2008;15:1375-1382.
24. Huang GW, Yang LY, Lu WQ. Expression of hypoxia-inducible factor 1α and vascular endothelial growth factor in hepatocellular carcinoma: impact on neovascularization and survival. World J Gastroenterol. 2005;21:1705-1708.
25. Neeman M, Gilad AA, Dafni H, et al. Molecular imaging of angiogenesis. J Magn Reson Imaging. 2007;25:1-12.
26. Zetser A, Bashenko Y, Edovitsky E, et al. Heparanase induces vascular endothelial growth factor expression: correlation with p38 phosphorylation levels and Src activation. Cancer Res. 2006;66:1455-1463.
27. Sato T, Yamaguchi A, Goi T, et al. Heparanase expression in human colorectal cancer and its relationship to tumor angiogenesis, hematogenous metastasis, and prognosis. J Surg Oncol. 2004;87:174-181.
28. Basche M, Gustafson DL, Holden SN, et al. A phase I biological and pharmacologic study of the heparanase inhibitor PI-88 in patients with advanced solid tumors. Clin Cancer Res. 2006;12:5471-5480.